Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Should real estate agents fear AI? Tushar Garg CEO at Flyhomes says no. He joined Cheddar to discuss the future of AI in the Real Estate business and more.
Christopher Zara, Senior Editor at Fast Company joined Cheddar to discuss the newly formed "DOGE"’s new goal to cut 2-trillion dollars from federal spending.
Sharon Price John CEO and President at Build-A-Bear Workshop discusses leading the brand, new offerings, the status of Brick-and-Mortar experiences and more!
A message left at the scene of an insurance executive’s fatal shooting echoes a phrase commonly used to describe insurer tactics to avoid paying claims.
Ryan Serhant, Founder and CEO of SERHANT, discusses the current Real Estate Market, the launch of S.MPLE by SERHANT, Season 2 of Owning Manhattan and more.
